NATACYN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NATACYN (NATACYN).
Natamycin is a polyene antifungal that binds to ergosterol in fungal cell membranes, increasing permeability and causing cell death.
| Metabolism | Not systemically absorbed; hepatic metabolism unlikely due to topical ophthalmic route. |
| Excretion | Primarily fecal via biliary elimination; less than 5% renal excretion of absorbed dose. |
| Half-life | Not well characterized due to minimal systemic absorption; estimated to be 2-3 hours in plasma if absorbed. |
| Protein binding | >90% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Very low, estimated <0.1 L/kg due to minimal systemic absorption; Vd not clinically relevant. |
| Bioavailability | Negligible (<0.5%) after ophthalmic or topical administration due to poor absorption; not administered orally or parenterally. |
| Onset of Action | Ophthalmic: clinical effect within 24-48 hours for Candida keratitis; topical administration. |
| Duration of Action | Ophthalmic: continued therapy for 14-21 days to prevent relapse; duration depends on infection severity. |
One drop of 5% ophthalmic suspension into the conjunctival sac every 1-2 hours for 48 hours, then taper to one drop 4-6 times daily.
| Dosage form | SUSPENSION |
| Renal impairment | No adjustment required. |
| Liver impairment | No adjustment required. |
| Pediatric use | Same as adult dosing: one drop of 5% ophthalmic suspension into the conjunctival sac every 1-2 hours, then taper. |
| Geriatric use | Same as adult dosing. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NATACYN (NATACYN).
| Breastfeeding | Due to negligible systemic absorption after topical ocular use, excretion into breast milk is unlikely. Caution is advised as no human data exist. M/P ratio: not applicable due to minimal systemic levels. |
| Teratogenic Risk | Natacyn (natamycin) is a polyene antifungal ophthalmic suspension. Systemic absorption is negligible (<1%) after topical ocular administration. No adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Based on minimal systemic exposure, risk to fetus is considered low. However, use during pregnancy only if clearly needed. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to natamycin or any component of the formulation"]
| Precautions | ["Not for injection","May cause corneal opacities with prolonged use","Discontinue if hypersensitivity occurs"] |
Loading safety data…
| Fetal Monitoring | No specific monitoring required beyond standard ophthalmologic follow-up for the maternal infection being treated. |
| Fertility Effects | No known effects on fertility. Systemic exposure is negligible, making reproductive impact unlikely. |